Shape Therapeutics
Shape Therapeutics develops programmable RNA medicines that use AI and RNA technology to address genetic causes of disease. Its work includes RNA editing, next-generation AAV delivery and gene therapy manufacturing for pharmaceutical innovators developing treatments for rare genetic disorders and other diseases.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2018
- Type
- Corporation Seattle business license
- Employees
- 51–200
- Registered name
- Shape Therapeutics Inc Seattle business license
- Stage
- Series B
Is this your organization? Claim it
Engineered U7 snRNA Scaffold Substantially Increases ADAR-Mediated Programmable RNA Base Editing
Researchers report that an engineered U7 small nuclear RNA scaffold substantially boosts ADAR-mediated programmable RNA base editing efficiency, offering a potential advance for RNA editing technologies.
Shape Therapeutics and UCSD Collaborators Review RNA Editing Progress and Clinical Challenges in Molecular Therapy
The article reviews advances in therapeutic RNA editing, highlighting its reversible, tunable benefits over DNA editing and summarizing challenges—guide RNA design, delivery, manufacturing, and assays for safety and efficacy—needed to advance clinical development.
ShapeTX announces AI-driven RNA therapies to repair genetic disease without permanent DNA edits
Shape Therapeutics says AI-driven RNA therapies can treat disease at its genetic root more safely than DNA editing, enabling programmable, localized medicines that avoid permanent genome changes and large foreign proteins.
See all 7 stories, episodes and videos about Shape Therapeutics.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
David Huss Executive, Chief Scientific Officer and Interim CEO
-
Francois Vigneault Former founder